Publications by authors named "M Vrtovec"
Article Synopsis
- The V617F mutation is linked to clonal hemopoiesis and faster progression of cardiovascular diseases, but its relationship with coronary artery atherosclerosis is not well understood.
- A study followed 36 patients with essential thrombocythemia (ET) and 38 healthy controls over four years to assess mutation burden and coronary calcium levels.
- While the overall mutation burden decreased, an increase in mutation burden correlated with a rise in coronary calcium scores, suggesting the mutation may contribute to atherosclerosis as a non-classical cardiovascular risk factor.
Background And Aims: Patients with myeloproliferative neoplasms often succumb to cardiovascular events, but little is known on the early stages of their vascular disease. We studied how patients with JAK2 V617F positive essential thrombocythemia (ET) without overt atherosclerotic disease differed from control subjects in the progression of carotid artery stiffness and preclinical atherosclerosis.
Methods: Thirty-six patients with JAK2 V617F positive ET and 38 age-, gender- and Framingham coronary heart disease (CHD) -matched control subjects were examined twice within 4 years.
Background: Patients with myeloproliferative neoplasms (MPNs) are at increased risk for atherothrombotic events. Our aim was to determine if patients with essential thrombocytosis (ET), a subtype of MPNs, free of symptomatic atherosclerosis, have greater carotid artery stiffness, worse endothelial function, greater coronary calcium and carotid plaque burden than control subjects.
Patients And Methods: 40 ET patients without overt vascular disease, and 42 apparently healthy, age and sex-matched control subjects with comparable classical risk factors for atherosclerosis and Framingham risk of coronary disease were enrolled.
Objective: Our prospective, randomized, open-label study assessed the efficacy of a heart rate-lowering, adjusted-dose protocol with ivabradine prior to coronary computed tomographic angiography (CCTA).
Methods: Patients undergoing CCTA were randomized to 7 days of adjusted-dose ivabradine or standard care (ie, no additional medication). Heart rate and β-blocker and antianxiety medication use on the day of the CCTA were recorded.
Background: The outcome of percutaneous transluminal angioplasty (PTA) of peripheral arterial lesions is influenced by several factors, including the haemodynamic conditions. Our study tested: (a) whether infrapopliteal run-off after completed PTA influenced the time course of restenosis/reocclusion of the femoropopliteal arterial segment, and (b) whether worsening of infrapopliteal run-off influenced the long-term femoropopliteal patency after PTA.
Patients And Methods: Among 245 patients treated by femoropopliteal PTA we enrolled 176 patients who consented to regular follow-up.